Rectal Cancer - Pipeline Review, H1 2018

Date: February 20, 2018
Pages: 112
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RF20B4B2A94EN
Leaflet:

Download PDF Leaflet

Rectal Cancer - Pipeline Review, H1 2018
Rectal Cancer - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer - Pipeline Review, H1 2018, provides an overview of the Rectal Cancer (Oncology) pipeline landscape.

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting. Rectal cancer treatment includes surgery, radiation therapy or chemotherapy, or a combination of these approaches

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rectal Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Discovery stages are 1, 6, 4 and 1 respectively.

Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Rectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rectal Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rectal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Rectal Cancer - Overview
Rectal Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Rectal Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rectal Cancer - Companies Involved in Therapeutics Development
AbbVie Inc
Advaxis Inc
Amgen Inc
Avid Bioservices Inc
Eisai Co Ltd
Eli Lilly and Co
GlaxoSmithKline Plc
Madrigal Pharmaceuticals Inc.
Merck KGaA
NewLink Genetics Corp
Taiwan Liposome Company Ltd
Rectal Cancer - Drug Profiles
AK-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
axalimogene filolisbac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bavituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevacizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRLX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-7046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galunisertib monohydrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ganetespib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2256098 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-7824 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLC-388 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rectal Cancer - Dormant Projects
Rectal Cancer - Product Development Milestones
Featured News & Press Releases
Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting
Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Rectal Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Rectal Cancer - Pipeline by AbbVie Inc, H1 2018
Rectal Cancer - Pipeline by Advaxis Inc, H1 2018
Rectal Cancer - Pipeline by Amgen Inc, H1 2018
Rectal Cancer - Pipeline by Avid Bioservices Inc, H1 2018
Rectal Cancer - Pipeline by Eisai Co Ltd, H1 2018
Rectal Cancer - Pipeline by Eli Lilly and Co, H1 2018
Rectal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2018
Rectal Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H1 2018
Rectal Cancer - Pipeline by Merck KGaA, H1 2018
Rectal Cancer - Pipeline by NewLink Genetics Corp, H1 2018
Rectal Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2018
Rectal Cancer - Dormant Projects, H1 2018

LIST OF FIGURES

Number of Products under Development for Rectal Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

AbbVie Inc
Advaxis Inc
Amgen Inc
Avid Bioservices Inc
Eisai Co Ltd
Eli Lilly and Co
GlaxoSmithKline Plc
Madrigal Pharmaceuticals Inc.
Merck KGaA
NewLink Genetics Corp
Taiwan Liposome Company Ltd
Skip to top


Medullary Thyroid Cancer - Pipeline Review, H1 2016 US$ 2,000.00 Mar, 2016 · 97 pages
Nasopharyngeal Cancer - Pipeline Review, H1 2018 US$ 2,000.00 Feb, 2018 · 370 pages
Rectal Cancer - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 128 pages
Anaplastic Thyroid Cancer - Pipeline Review, H1 2016 US$ 2,000.00 Feb, 2016 · 85 pages

Ask Your Question

Rectal Cancer - Pipeline Review, H1 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: